Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis
Status:
RECRUITING
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This study will examine the effectiveness of administering adalimumab as a treatment for patients in the early stages of steroid-dependent immune checkpoint Inhibitor associated inflammatory arthritis (ir-IA). Adalimumab (ADA) is a TNF inhibitor (TNFi) that is well established as a standard of care treatment for numerous types of inflammatory arthritis. It is hoped that adalimumab at the early stages of the ir-IA will reduce the symptoms and therefore reduce the need for steroids. This study is a pragmatic randomized clinical trial. Patients will be randomized 1:1 to each treatment group. To evaluate the steroid sparing effect of early induction six doses of Adalimumab will be administered to patients in the study treatment arm as compared to the usual standard of care of a predefined corticosteroid regimen and taper at 12 weeks administered in the control group.
Phase:
PHASE2
Details
Lead Sponsor:
Tom Appleton
Collaborators:
Canadian Research Group in Immuno-Oncology Western University